臨床試驗

Study of Sonodynamic Therapy in Participants With Recurrent High-Grade Glioma

NCT：NCT04559685 · TERMINATED

NCT IDNCT04559685

狀態TERMINATED

開始日期2021-03-15

完成時間2024-11-10

SponsorNader Sanai (OTHER)

First posted2020-09-23

Last updated2026-05-14

簡要摘要

A Phase 0 single center, first in human, open-label study of ascending energy doses of sonodynamic therapy (SDT) utilizing the MRgFUS combined with intravenous ALA to assess safety and efficacy in up to 45 participants with recurrent HGG. Eligible participants who are scheduled for resection will be administered intravenous (IV) aminolevulinic acid HCl (ALA) approximately six to seven (6-7) hours prior to receiving sonodynamic therapy (SDT).

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。